Lead Product(s) : Tucidinostat,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUYABIO Shares Positive Phase 2 Data On HBI-8000 and Nivolumab for Melanoma
Details :
Product Name : Hiyasta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2024
Lead Product(s) : Tucidinostat,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan
Details :
Product Name : Hiyasta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Meiji Seika Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details :
Product Name : Hiyasta
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Meiji Seika Pharma
Deal Size : Undisclosed
Deal Type : Collaboration